Bin Wu, Ph.D.
Founder, President, and CEO
Bin founded Phosphorex in 2005 with a goal of creating a global leader in drug delivery and pharmaceutical formulation. Before founding the company, he held senior technical positions in various companies including UCB, Kimberly-Clark and Du Pont. As an expert in biomaterials, controlled release, targeted drug delivery and nanomedicine, Bin published scientific articles in numerous peer-reviewed journals and is the inventor of 20 granted US patents and 28 international PCT applications. Bin received his Ph.D. in polymer chemistry from the University of Massachusetts Amherst, and a B.S. in polymer technology and engineering from Hefei Polytechnical University.
Julia Rashba-Step, Ph.D.
Vice President, R&D and Alliance Management
Julia is a senior pharmaceutical professional with extensive background in biotechnology and pharmaceutical sciences. Julia has worked in both small and large pharmaceutical companies including Baxter, Wyeth and Pfizer, where she held positions of growing responsibilities. Prior to joining Phosphorex in 2017, Julia led the Novel Delivery Technologies group at Pfizer. At Phosphorex, Julia works closely with pharma and biotech partners to help advance cutting-edge, innovative concepts into critical programs. Julia’s technical background is in pharmaceutical product development with the focus on advanced formulations and drug delivery. She is passionate about translating patient-centric innovations into commercially viable products. Julia has been an invited speaker at various drug delivery conferences and workshops. She received her Ph.D. in Biophysics from Russian Academy of Sciences and did her postdoctoral work at Mount Sinai Hospital in New York. Julia is an active member of Massachusetts Biotechnology Council’s Mentors group.
Director, Process Development
Matt has extensive expertise in process/product development and manufacturing of a broad range of biologics and parental drug products, especially in drug products of complex processes. Prior to joining Phosphorex, he was associate director of manufacturing at Selecta Biosciences where he was responsible for process scale-up and tech transfer activities from internal process development lab to external CMOs for the production of complex parental drug products for clinical trials. Prior to that, Matt was at Alexion Pharmaceuticals where he was responsible for authoring and editing global CMC CTD documents and responses to support new drug product manufacturer and process changes for commercial and development products. Matt was a senior process engineer at Eisai where he managed the cGMP manufacturing operations for two biologic products. Earlier in his career, Matt was senior manager of manufacturing at RenaMed Biologics, a principle engineer at Baxter Healthcare, and a clinical production supervisor at Cyto Therapeutics, Inc. Matt received his B.S. in mechanical and biomedical engineering at Worcester Polytechnic Institute.
Director, Program Management
Theresa has led more than twenty projects for pharma and biotech clients, coordinating all aspects of development and manufacturing of microspheres, nanoparticles and nanocrystals for preclinical and clinical studies. In this role, Theresa is responsible for managing all stages of drug delivery projects, from proof of concept to clinical trials and helping to accelerate progress towards the clinic for clients. Theresa received her B.S. in chemical engineering and an M.S. in biomedical engineering, both from Worcester Polytechnic Institute.
Nicholas Boylan, Ph.D.
Associate Director, Product and Technology Development
Nick brings over 10 years of experience in drug delivery research and development, both in industry and academia. Prior to joining Phosphorex in 2020, Nick worked on polymer and lipid nanoparticles and nanoemulsions at several companies and institutes including Molecular Infusions, Bind Therapeutics, Wolfe Laboratories and Johns Hopkins University. Nick obtained his Ph.D. in chemical and biomedical engineering from Johns Hopkins University and his B.S. from Cornell University.
Sue Madaio, SPHR
Human Resource Manager
Sue has more than twenty years of progressive experience in human resources, primarily working at global technology companies including Staples, IDC (International Data Corporation), Hewlett Packard, Compaq and Digital Equipment Corporation, which afforded her the opportunity to be part of organizations undergoing major technology and leadership changes, transformation, mergers and acquisitions. She has expertise in talent acquisition, talent management and succession planning, performance management, total rewards, policy implementation and interpretation. She obtained her SPHR certification in 1998 and earned a B.A. in Spanish from Westfield State University.
Stephen Zale, Ph.D.
Stephen is a development scientist and subject matter expert on pharmaceutical formulations, drug delivery and biomaterials. Leveraging his 30 years of experience in the industry, Stephen advises the company in formulation development, pharmaceutical sciences, drug delivery technology and program management. Previously, Stephen was Vice President of Development and founding scientist at BIND Therapeutics (acquired by Pfizer in 2016), and was Vice President of Injectable Products R&D at Alkermes where he led the group responsible for developing Alkermes' biodegradable polymer-based microsphere products, including Risperdal Consta, Vivitrol and Bydureon. Stephen received a Ph.D. in Biochemical Engineering and a B.S. in Chemistry, both from MIT.
Business Development Advisor
Dan is currently Chief Business Officer of Ventus Therapeutics. Previously Dan was Chief Business Officer at Arrakis Therapeutics and BIND Therapeutics and held positions at Biogen in Corporate Development, Discovery Research, and Commercial Operations. He founded and served as President of Biogen’s biosimilars business. Dan is deeply experienced in building high-growth organizations in the US and abroad, designing and implementing creative strategies to build corporate value, financing innovative companies from inception through IPO, negotiating and managing corporate collaborations, and leading groups of diverse functional experts. Dan received an MBA from Harvard Business School and a B.S. in Biochemistry from Boston College.